{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:13:22Z","timestamp":1775715202190,"version":"3.50.1"},"publisher-location":"Singapore","reference-count":111,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811602665","type":"print"},{"value":"9789811602672","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-981-16-0267-2_10","type":"book-chapter","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T20:02:36Z","timestamp":1626206556000},"page":"261-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Peptide-Based Antiviral Drugs"],"prefix":"10.1007","author":[{"given":"N. Arul","family":"Murugan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Muruga Poopathi","family":"Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. T.","family":"Saraswathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"xiii","DOI":"10.1016\/j.idc.2019.09.001","volume":"33","author":"A Zumla","year":"2019","unstructured":"Zumla A, Hui DS (2019) Emerging and reemerging infectious diseases global overview. Infect Dis Clin North Am 33:xiii\u2013xix","journal-title":"Infect Dis Clin North Am"},{"key":"10_CR2","volume-title":"Fmoc solid phase peptide synthesis: a practical approach","year":"1999","unstructured":"Chan WC, White P (eds) (1999) Fmoc solid phase peptide synthesis: a practical approach. OUP Oxford, Oxford, UK"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1021\/jm1002183","volume":"53","author":"T Matsubara","year":"2010","unstructured":"Matsubara T, Onishi A, Saito T, Shimada A, Inoue H, Taki T, Nagata K, Okahata Y, Sato T (2010) Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. J Med Chem 53:4441\u20134449","journal-title":"J Med Chem"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nature05114","volume":"443","author":"RJ Russell","year":"2006","unstructured":"Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45\u201349","journal-title":"Nature"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"18979","DOI":"10.1073\/pnas.1013387107","volume":"107","author":"TT Wang","year":"2010","unstructured":"Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, Garc\u00eda-Sastre A, Moran TM, Palese P (2010) Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 107:18979\u201318984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.qco.0000200293.45532.68","volume":"19","author":"AM Geretti","year":"2006","unstructured":"Geretti AM (2006) HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 19:1\u20137","journal-title":"Curr Opin Infect Dis"},{"key":"10_CR7","doi-asserted-by":"crossref","unstructured":"Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, Schiller JT (2006) Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 103:1516\u20131521","DOI":"10.1073\/pnas.0508033103"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nsmb.1456","volume":"15","author":"SC Harrison","year":"2008","unstructured":"Harrison SC (2008) Viral membrane fusion. Nat Struct Mol Biol 15:690\u2013698","journal-title":"Nat Struct Mol Biol"},{"key":"10_CR9","doi-asserted-by":"crossref","unstructured":"Ingallinella P, Bianchi E, Ladwa NA, Wang YJ, Hrin R, Veneziano M, Bonelli F, Ketas TJ, Moore JP, Miller MD, Pessi A (2009) Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A 106:5801\u20135806","DOI":"10.1073\/pnas.0901007106"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2146\/ajhp110123","volume":"69","author":"JJ Kim","year":"2012","unstructured":"Kim JJ, Culley CM, Mohammad RA (2012) Telaprevir: an oral protease inhibitor for hepatitis C virus infection. American journal of health-system pharmacy. Am J Health Syst Pharm 69:19\u201333","journal-title":"Am J Health Syst Pharm"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fmicb.2013.00321","volume":"4","author":"K Mulder","year":"2013","unstructured":"Mulder K, Lima LA, Miranda V, Dias SC, Franco OL (2013) Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides. Front Microbiol 4:321","journal-title":"Front Microbiol"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fchem.2014.00062","volume":"2","author":"L Otvos Jr","year":"2014","unstructured":"Otvos L Jr, Wade JD (2014) Current challenges in peptide-based drug discovery. Front Chem 2:62","journal-title":"Front Chem"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep36617","volume":"6","author":"D Mathur","year":"2016","unstructured":"Mathur D, Prakash S, Anand P, Kaur H, Agrawal P, Mehta A, Kumar R, Singh S, Raghava GP (2016) PEPlife:a repository of the half-life of peptides. Sci Rep 6:1\u20137","journal-title":"Sci Rep"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00726-005-0289-3","volume":"30","author":"M Werle","year":"2006","unstructured":"Werle M, Bernkop-Schn\u00fcrch A (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30:351\u2013367","journal-title":"Amino Acids"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/bip.22877","volume":"106","author":"DP Fairlie","year":"2016","unstructured":"Fairlie DP, Dantas de Araujo A (2016) Stapling peptides using cysteine crosslinking. Pept Sci 106:843\u2013852","journal-title":"Pept Sci"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"8773","DOI":"10.1021\/acs.jmedchem.9b00882","volume":"62","author":"G Meng","year":"2019","unstructured":"Meng G, Pu J, Li Y, Han A, Tian Y, Xu W, Zhang T, Li X, Lu L, Wang C, Jiang S (2019) Design and biological evaluation of m-xylene Thioether-stapled short helical peptides targeting the HIV-1 gp41 Hexameric coiled\u2013coil fusion complex. J Med Chem 62:8773\u20138783","journal-title":"J Med Chem"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1021\/acs.jmedchem.7b01732","volume":"61","author":"C Wang","year":"2018","unstructured":"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K (2018) Discovery of hydrocarbon-stapled short \u03b1-helical peptides as promising middle east respiratory syndrome coronavirus (MERS-CoV) fusion inhibitors. J Med Chem 61:2018\u20132026","journal-title":"J Med Chem"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1021\/jm5016582","volume":"58","author":"S Cheng","year":"2015","unstructured":"Cheng S, Chang X, Wang Y, Gao GF, Shao Y, Ma L, Li X (2015) Glycosylated enfuvirtide: a long-lasting glycopeptide with potent anti-HIV activity. J Med Chem 58:1372\u20131379","journal-title":"J Med Chem"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"115306","DOI":"10.1016\/j.bmc.2020.115306","volume":"28","author":"M Fu","year":"2020","unstructured":"Fu M, Zhuang X, Zhang T, Guan Y, Meng Q, Zhang Y (2020) PEGylated leuprolide with improved pharmacokinetic properties. Bioorg Med Chem 28:115306","journal-title":"Bioorg Med Chem"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451\u20131458","journal-title":"Drug Discov Today"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1039\/c3cs60384a","volume":"43","author":"I Avan","year":"2014","unstructured":"Avan I, Hall CD, Katritzky AR (2014) Peptidomimetics via modifications of amino acids and peptide bonds. Chem Soc Rev 43:3575\u20133594","journal-title":"Chem Soc Rev"},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2174\/138527208783743697","volume":"12","author":"U Kazmaier","year":"2008","unstructured":"Kazmaier U, Deska J (2008) Peptide backbone modifications. Curr Org Chem 12:355\u2013385","journal-title":"Curr Org Chem"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/acs.biochem.7b00861","volume":"57","author":"MM M\u00fcller","year":"2018","unstructured":"M\u00fcller MM (2018) Post-translational modifications of protein backbones: unique functions, mechanisms, and challenges. Biochemistry 57:177\u2013185","journal-title":"Biochemistry"},{"key":"10_CR24","doi-asserted-by":"crossref","unstructured":"Tugyi R, Uray K, Iv\u00e1n D, Fellinger E, Perkins A, Hudecz F (2005) Partial D-amino acid substitution: improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci U S A 102:413\u2013418","DOI":"10.1073\/pnas.0407677102"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.tetlet.2017.12.035","volume":"59","author":"J Wu","year":"2018","unstructured":"Wu J, Tang J, Chen H, He Y, Wang H, Yao H (2018) Recent developments in peptide macrocyclization. Tetrahedron Lett 59:325\u2013333","journal-title":"Tetrahedron Lett"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/anie.199416991","volume":"33","author":"J Gante","year":"1994","unstructured":"Gante J (1994) Peptidomimetics\u2014tailored enzyme inhibitors. Angew Chem Int Ed Engl 33:1699\u20131720","journal-title":"Angew Chem Int Ed Engl"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1473-3099(02)00465-6","volume":"2","author":"C Orellana","year":"2002","unstructured":"Orellana C (2002) Immune system stimulator shows promise against tuberculosis. Lancet Infect Dis 2:711","journal-title":"Lancet Infect Dis"},{"key":"10_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1039\/c0md00020e","volume":"1","author":"JL Reymond","year":"2010","unstructured":"Reymond JL, Van Deursen R, Blum LC, Ruddigkeit L (2010) Chemical space as a source for new drugs. MedChemComm 1:30\u201338","journal-title":"MedChemComm"},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.3389\/fmicb.2019.02764","volume":"10","author":"H Takahashi","year":"2019","unstructured":"Takahashi H, Fukuhara T, Kitazawa H, Kormelink R (2019) Virus latency and the impact on plants. Front Microbiol 10:2764","journal-title":"Front Microbiol"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/j.1364-3703.2011.00752.x","volume":"12","author":"KB Scholthof","year":"2011","unstructured":"Scholthof KB, Adkins S, Czosnek H, Palukaitis P, Jacquot E, Hohn T, Hohn B, Saunders K, Candresse T, Ahlquist P, Hemenway C (2011) Top 10 plant viruses in molecular plant pathology. Mol Plant Pathol 12:938\u2013954","journal-title":"Mol Plant Pathol"},{"key":"10_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/0022-1317-67-1-1","volume":"67","author":"HB Ohmann","year":"1986","unstructured":"Ohmann HB, Babiuk LA (1986) Viral infections in domestic animals as models for studies of viral immunology and pathogenesis. J Gen Virol 67:1\u201325","journal-title":"J Gen Virol"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1098\/rstb.2011.0354","volume":"367","author":"M Woolhouse","year":"2012","unstructured":"Woolhouse M, Scott F, Hudson Z, Howey R, Chase-Topping M (2012) Human viruses: discovery and emergence. Philos Trans R Soc Lond Ser B Biol Sci 367:2864\u20132871","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","volume":"26","author":"JL Lau","year":"2018","unstructured":"Lau JL, Dunn MK (2018) Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem 26:2700\u20132707","journal-title":"Bioorg Med Chem"},{"key":"10_CR34","first-page":"1","volume":"18","author":"G Agarwal","year":"2020","unstructured":"Agarwal G, Gabrani R (2020) Antiviral peptides: identification and validation. Int J Pept Res Ther 18:1\u201320","journal-title":"Int J Pept Res Ther"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"28821","DOI":"10.1074\/jbc.M112.375949","volume":"287","author":"LH Demirkhanyan","year":"2012","unstructured":"Demirkhanyan LH, Marin M, Padilla-Parra S, Zhan C, Miyauchi K, Jean-Baptiste M (2012) Multifaceted mechanisms of HIV-1 entry inhibition by human alpha-defensin. J Biol Chem 287:28821\u201328838","journal-title":"J Biol Chem"},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2174\/1381612043384448","volume":"10","author":"MJ Root","year":"2004","unstructured":"Root MJ, Steger HK (2004) HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 10:1805\u20131825","journal-title":"Curr Pharm Des"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/hep.21102","volume":"43","author":"J Paeshuyse","year":"2006","unstructured":"Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, Bartenschlager R, Neyts J (2006) The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43:761\u2013770","journal-title":"Hepatology"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nrd2336","volume":"6","author":"C Flexner","year":"2007","unstructured":"Flexner C (2007) HIV drug development: the next 25 years. Nat Rev Drug Discov 6:959\u2013966","journal-title":"Nat Rev Drug Discov"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/cmdc.201000289","volume":"5","author":"L Cai","year":"2010","unstructured":"Cai L, Jiang S (2010) Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. Chem Med Chem 5:1813\u20131824","journal-title":"Chem Med Chem"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1517\/13543776.2014.987752","volume":"25","author":"D Zhang","year":"2015","unstructured":"Zhang D, Li W, Jiang S (2015) Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009\u20132014). Expert Opin Ther Pat 25:159\u2013173","journal-title":"Expert Opin Ther Pat"},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"e32599","DOI":"10.1371\/journal.pone.0032599","volume":"7","author":"H Chong","year":"2012","unstructured":"Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, He Y (2012) Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One 7:e32599","journal-title":"PLoS One"},{"key":"10_CR42","doi-asserted-by":"publisher","first-page":"11126","DOI":"10.1074\/jbc.M800200200","volume":"283","author":"Y He","year":"2008","unstructured":"He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X, Lu H, Jing W, Jiang S, Zhang L (2008) Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 283:11126\u201311134","journal-title":"J Biol Chem"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.bbrc.2009.03.057","volume":"382","author":"RR Wang","year":"2009","unstructured":"Wang RR, Yang LM, Wang YH, Pang W, Tam SC, Tien P, Zheng YT (2009) Sifuvirtide, a potent HIV fusion inhibitor peptide. Biochem Biophys Res Commun 382:540\u2013544","journal-title":"Biochem Biophys Res Commun"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1128\/AAC.00976-09","volume":"54","author":"D Xie","year":"2010","unstructured":"Xie D, Yao C, Wang L, Min W, Xu J, Xiao J, Huang M, Chen B, Liu B, Li X, Jiang H (2010) An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 54:191\u2013196","journal-title":"Antimicrob Agents Chemother"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"e3155","DOI":"10.1002\/psc.3155","volume":"25","author":"R Aneja","year":"2019","unstructured":"Aneja R, Grigoletto A, Nangarlia A, Rashad AA, Wrenn S, Jacobson JM, Pasut G, Chaiken I (2019) Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes. J Pept Sci 25:e3155","journal-title":"J Pept Sci"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1021\/jm070814r","volume":"51","author":"H Gopi","year":"2008","unstructured":"Gopi H, Umashankara M, Pirrone V, LaLonde J, Madani N, Tuzer F, Baxter S, Zentner I, Cocklin S, Jawanda N, Miller SR (2008) Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem 51:2638\u20132647","journal-title":"J Med Chem"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nbt1267","volume":"24","author":"RE Hancock","year":"2006","unstructured":"Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24:1551\u20131557","journal-title":"Nat Biotechnol"},{"key":"10_CR48","unstructured":"National Center for Biotechnology Information (2020) PubChem Compound Summary for CID 100094, Oglufanide. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Oglufanide"},{"key":"10_CR49","doi-asserted-by":"crossref","unstructured":"Chen Q, Guo Y (2016) Influenza viral hemagglutinin peptide inhibits influenza viral entry by shielding the host receptor. ACS Infect Dis 2:187\u2013193","DOI":"10.1021\/acsinfecdis.5b00139"},{"key":"10_CR50","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.3390\/v7102883","volume":"7","author":"S Skalickova","year":"2015","unstructured":"Skalickova S, Heger Z, Krejcova L, Pekarik V, Bastl K, Janda J, Kostolansky F, Vareckova E, Zitka O, Adam V, Kizek R (2015) Perspective of use of antiviral peptides against influenza virus. Viruses 7:5428\u20135442","journal-title":"Viruses"},{"key":"10_CR51","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.3390\/v5122977","volume":"5","author":"SP Lim","year":"2013","unstructured":"Lim SP, Shi PY (2013) West Nile virus drug discovery. Viruses 5:2977\u20133006","journal-title":"Viruses"},{"key":"10_CR52","doi-asserted-by":"crossref","unstructured":"Hrobowski YM, Garry RF, Michael SF (2005) Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J 2:49","DOI":"10.1186\/1743-422X-2-49"},{"key":"10_CR53","first-page":"4155","volume":"10","author":"S VanPatten","year":"2020","unstructured":"VanPatten S, He M, Altiti A, F Cheng K, Ghanem MH, Al-Abed Y (2020) Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. Future Med Chem 10:4155","journal-title":"Future Med Chem"},{"key":"10_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms16092","volume":"8","author":"A Zorzi","year":"2017","unstructured":"Zorzi A, Middendorp SJ, Wilbs J, Deyle K, Heinis C (2017) Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. Nat Commun 8:1\u20139","journal-title":"Nat Commun"},{"key":"10_CR55","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3390\/v10120721","volume":"10","author":"R Liang","year":"2018","unstructured":"Liang R, Wang L, Zhang N, Deng X, Su M, Su Y, Hu L, He C, Ying T, Jiang S, Yu F (2018) Development of small-molecule MERS-CoV inhibitors. Viruses 10:721","journal-title":"Viruses"},{"key":"10_CR56","doi-asserted-by":"publisher","first-page":"19403","DOI":"10.1074\/jbc.M115.651463","volume":"290","author":"S Tomar","year":"2015","unstructured":"Tomar S, Johnston ML, John SES, Osswald HL, Nyalapatla PR, Paul LN, Ghosh AK, Denison MR, Mesecar AD (2015) Ligand-induced dimerization of middle east respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro) implications for nsp5 regulation and the development of antivirals. J Biol Chem 290:19403\u201319422","journal-title":"J Biol Chem"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"13134","DOI":"10.1128\/JVI.02433-13","volume":"87","author":"J Gao","year":"2013","unstructured":"Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, Geng H, Li H, Wang Q, Xiao H, Tan W (2013) Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol 87:13134\u201313140","journal-title":"J Virol"},{"key":"10_CR58","first-page":"1","volume":"5","author":"L Lu","year":"2014","unstructured":"Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F, Ma C (2014) Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 5:1\u20132","journal-title":"Nat Commun"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/jmv.25736","volume":"92","author":"M Bhattacharya","year":"2020","unstructured":"Bhattacharya M, Sharma AR, Patra P, Ghosh P, Sharma G, Patra BC, Lee SS, Chakraborty C (2020) Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. J Med Virol 92:618\u2013631","journal-title":"J Med Virol"},{"key":"10_CR60","doi-asserted-by":"publisher","first-page":"eabb8097","DOI":"10.1126\/sciadv.abb8097","volume":"6","author":"PK Panda","year":"2020","unstructured":"Panda PK, Murugan NA, Patel P, Verma SK, Luo W, Rubahn H-G, Mishra YK, Suar M, Ahuja R (2020) Structure-based drug designing and immunoinformatics approach for SARS-CoV-2. Sci Adv 6:eabb8097","journal-title":"Sci Adv"},{"key":"10_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1777901","volume":"2020","author":"NA Murugan","year":"2020","unstructured":"Murugan NA, Pandian CJ, Jeyakanthan J (2020) Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials. J Biomol Struct Dyn 2020:1\u201312. https:\/\/doi.org\/10.1080\/07391102.2020.1777901","journal-title":"J Biomol Struct Dyn"},{"key":"10_CR62","doi-asserted-by":"crossref","unstructured":"Badani H, Garry RF, Wimley WC (2014) Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity. Biochim Biophys Acta 1838:2180\u20132197","DOI":"10.1016\/j.bbamem.2014.04.015"},{"key":"10_CR63","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y (2020) Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289\u2013293","journal-title":"Nature"},{"key":"10_CR64","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/pharmaceutics11090443","volume":"11","author":"A Majkowska-Pilip","year":"2019","unstructured":"Majkowska-Pilip A, Halik PK, Gniazdowska E (2019) The significance of NK1 receptor ligands and their application in targeted radionuclide tumour therapy. Pharmaceutics 11:443","journal-title":"Pharmaceutics"},{"key":"10_CR65","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1021\/acsnano.0c02857","volume":"14","author":"Y Han","year":"2020","unstructured":"Han Y, Kr\u00e1l P (2020) Computational design of ACE2-based peptide inhibitors of SARS-CoV-2. ACS Nano 14:5143\u20135147","journal-title":"ACS Nano"},{"key":"10_CR66","first-page":"690","volume":"15","author":"W Weissenhorn","year":"2007","unstructured":"Weissenhorn W, Hinz A, Gaudin Y (2007) Virus membrane fusion. FEBS Lett 15:690\u2013698","journal-title":"FEBS Lett"},{"key":"10_CR67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/07391102.2002.10506820","volume":"20","author":"GS Rao","year":"2002","unstructured":"Rao GS, Bhatnagar S, Ahuja V (2002) Structure-based design of a novel peptide inhibitor of HIV-1 integrase: a computer modeling approach. J Biomol Struct Dyn 20:31\u201338","journal-title":"J Biomol Struct Dyn"},{"key":"10_CR68","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.virusres.2014.10.007","volume":"194","author":"S Xia","year":"2014","unstructured":"Xia S, Liu Q, Wang Q, Sun ZW, Su S, Dub LY, Ying TL, Lu L, Jiang SB (2014) Middle east respiratory syndrome coronavirus (mers-cov) entry inhibitors targeting spike protein. Virus Res 194:200\u2013210","journal-title":"Virus Res"},{"key":"10_CR69","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1021\/acs.langmuir.9b01052","volume":"35","author":"S Park","year":"2019","unstructured":"Park S, Jackman JA, Cho NJ (2019) Comparing the membrane-interaction profiles of two antiviral peptides: insights into structure\u2013function relationship. Langmuir 35:9934\u20139943","journal-title":"Langmuir"},{"key":"10_CR70","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1128\/JVI.77.10.6055-6061.2003","volume":"77","author":"M Elazar","year":"2003","unstructured":"Elazar M, Cheong KH, Liu P, Greenberg HB, Rice CM, Glenn JS (2003) Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol 77:6055\u20136061","journal-title":"J Virol"},{"key":"10_CR71","volume-title":"Reactivity and structure: concepts in organic chemistry","author":"M Bodanszky","year":"2012","unstructured":"Bodanszky M (2012) Principles of peptide synthesis. In: Reactivity and structure: concepts in organic chemistry, vol 16. Springer, New York"},{"key":"10_CR72","volume-title":"Reactivity and structure: concepts in organic chemistry","author":"M Bodanszky","year":"2013","unstructured":"Bodanszky M, Bodanszky A (2013) The practice of peptide synthesis. In: Reactivity and structure: concepts in organic chemistry, vol 21. Springer, New York"},{"key":"10_CR73","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00726-017-2516-0","volume":"50","author":"MMJ Da\u2019san","year":"2018","unstructured":"Da\u2019san MMJ (2018) Thirteen decades of peptide synthesis: key developments in solid phase peptide synthesis and amide bond formation utilized in peptide ligation. Amino Acids 50:39\u201368","journal-title":"Amino Acids"},{"key":"10_CR74","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1399-3011.2005.00214.x","volume":"65","author":"T Kimmerlin","year":"2005","unstructured":"Kimmerlin T, Seebach D (2005) \u2018100 years of peptide synthesis\u2019: ligation methods for peptide and protein synthesis with applications to \u03b2-peptide assemblies. J Pept Res 65:229\u2013260","journal-title":"J Pept Res"},{"key":"10_CR75","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1021\/ja00897a025","volume":"85","author":"RB Merrifield","year":"1963","unstructured":"Merrifield RB (1963) Solid phase peptide synthesis I: the synthesis of a tetrapeptide. J Am Chem Soc 85:2149\u20132154","journal-title":"J Am Chem Soc"},{"key":"10_CR76","doi-asserted-by":"publisher","first-page":"9046","DOI":"10.1039\/C8CS00573G","volume":"47","author":"AC Conibear","year":"2018","unstructured":"Conibear AC, Watson EE, Payne RJ, Becker CF (2018) Native chemical ligation in protein synthesis and semi-synthesis. Chem Soc Rev 47:9046\u20139068","journal-title":"Chem Soc Rev"},{"key":"10_CR77","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1021\/jo00795a005","volume":"37","author":"LA Carpino","year":"1972","unstructured":"Carpino LA, Han GY (1972) 9-Fluorenylmethoxycarbonyl amino-protecting group. J Org Chem 37:3404\u20133409","journal-title":"J Org Chem"},{"key":"10_CR78","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cbpa.2017.03.014","volume":"38","author":"B Mishra","year":"2017","unstructured":"Mishra B, Reiling S, Zarena D, Wang G (2017) Host defense antimicrobial peptides as antibiotics: design and application strategies. Curr Opin Chem Biol 38:87\u201396","journal-title":"Curr Opin Chem Biol"},{"key":"10_CR79","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/02713680590934111","volume":"30","author":"YJ Gordon","year":"2005","unstructured":"Gordon YJ, Huang LC, Romanowski EG, Yate KA, Proske RJ, McDermott AM (2005) Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res 30:385\u2013394","journal-title":"Curr Eye Res"},{"key":"10_CR80","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1016\/j.jmb.2013.09.038","volume":"425","author":"SS Wilson","year":"2013","unstructured":"Wilson SS, Wiens ME, Smith JG (2013) Antiviral mechanisms of human defensins. J Mol Biol 425:4965\u20134980","journal-title":"J Mol Biol"},{"key":"10_CR81","doi-asserted-by":"publisher","first-page":"e76038","DOI":"10.1371\/journal.pone.0076038","volume":"8","author":"J Ding","year":"2013","unstructured":"Ding J, Tasker C, Valere K, Sihvonen T, Descalzi-Montoya DB, Lu W, Chang TL (2013) Anti-HIV activity of human defensin 5 in primary CD4+T cells under serum-deprived conditions is a consequence of defensin-mediated cytotoxicity. PLoS One 8:e76038","journal-title":"PLoS One"},{"key":"10_CR82","doi-asserted-by":"publisher","first-page":"31125","DOI":"10.1074\/jbc.M805902200","volume":"283","author":"AS Dugan","year":"2008","unstructured":"Dugan AS, Maginnis MS, Jordan JA, Gasparovic ML, Manley K, Page R (2008) Human alpha-defensins inhibit BK virus infection by aggregating virions and blocking binding to host cells. J Biol Chem 283:31125\u201331132","journal-title":"J Biol Chem"},{"key":"10_CR83","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/157016212799304580","volume":"10","author":"CR Eade","year":"2012","unstructured":"Eade CR, Wood MP, Cole AM (2012) Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development. Curr HIV Res 10:61\u201372","journal-title":"Curr HIV Res"},{"key":"10_CR84","doi-asserted-by":"publisher","first-page":"e45208","DOI":"10.1371\/journal.pone.0045208","volume":"7","author":"L Furci","year":"2012","unstructured":"Furci L, Tolazzi M, Sironi F, Vassena L, Lusso P (2012) Inhibition of HIV-1 infection by human alpha-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae. PLoS One 7:e45208","journal-title":"PLoS One"},{"key":"10_CR85","doi-asserted-by":"publisher","first-page":"8658","DOI":"10.4049\/jimmunol.177.12.8658","volume":"177","author":"E Hazrati","year":"2006","unstructured":"Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ (2006) Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 177:8658\u20138666","journal-title":"J Immunol"},{"key":"10_CR86","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1742-4690-8-45","volume":"8","author":"A Rapista","year":"2011","unstructured":"Rapista A, Ding J, Benito B, Lo YT, Neiditch MB, Lu W (2011) Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment. Retrovirology 8:45","journal-title":"Retrovirology"},{"key":"10_CR87","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.chom.2007.12.001","volume":"3","author":"JG Smith","year":"2008","unstructured":"Smith JG, Nemerow GR (2008) Mechanism of adenovirus neutralization by human alpha-defensins. Cell Host Microbe 3:11\u201319","journal-title":"Cell Host Microbe"},{"key":"10_CR88","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/biot.200700148","volume":"2","author":"C Verma","year":"2007","unstructured":"Verma C, Seebah S, Low SM, Zhou L, Liu SP, Li J (2007) Defensins: antimicrobial peptides for therapeutic development. Biotechnol J 2:1353\u20131359","journal-title":"Biotechnol J"},{"key":"10_CR89","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.4172\/2329-6798.1000e103","volume":"1","author":"L Sun","year":"2013","unstructured":"Sun L (2013) Peptide-based drug development. Mod Chem appl 1:e103","journal-title":"Mod Chem appl"},{"key":"10_CR90","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"K Fosgerau","year":"2015","unstructured":"Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20:122\u2013128","journal-title":"Drug Discov Today"},{"key":"10_CR91","first-page":"16","volume":"6","author":"K Muruga Poopathi Raja","year":"2016","unstructured":"Muruga Poopathi Raja K (2016) Biopharmaceuticals \u2013 emerging peptide therapeutics. Cutting Edge 6:16\u201320","journal-title":"Cutting Edge"},{"key":"10_CR92","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","volume":"17","author":"L Di","year":"2015","unstructured":"Di L (2015) Strategic approaches to optimizing peptide ADME properties. AAPS J 17:134\u2013143","journal-title":"AAPS J"},{"key":"10_CR93","doi-asserted-by":"publisher","first-page":"170328","DOI":"10.1016\/j.peptides.2020.170328","volume":"130","author":"R Ling","year":"2020","unstructured":"Ling R, Dai Y, Huang B, Huang W, Yu J, Lu X, Jiang Y (2020) In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2. Peptides 130:170328","journal-title":"Peptides"},{"key":"10_CR94","doi-asserted-by":"crossref","unstructured":"Pierce BG, Boucher EN, Piepenbrink KH, Ejemel M, Rapp CA, Thomas WD, Sundberg EJ, Weng Z, Wang Y (2017) Structure-based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a conserved epitope. J Virol 91:e01032\u201317","DOI":"10.1128\/JVI.01032-17"},{"key":"10_CR95","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2174\/157340606776930736","volume":"2","author":"R Zhang","year":"2006","unstructured":"Zhang R, Wei DQ, Du S, Chou KC (2006) Molecular modeling studies of peptide drug candidates against SARS. Med Chem 2:309\u2013314","journal-title":"Med Chem"},{"key":"10_CR96","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cbdd.13388","volume":"93","author":"MT Muhammed","year":"2019","unstructured":"Muhammed MT, Aki-Yalcin E (2019) Homology modeling in drug discovery: overview, current applications, and future perspectives. Chem Biol Drug Des 93:12\u201320","journal-title":"Chem Biol Drug Des"},{"key":"10_CR97","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.3390\/ijms11124932","volume":"11","author":"Z Yang","year":"2010","unstructured":"Yang Z, Yang G, Zu Y, Fu Y, Zhou L (2010) Computer-based de novo designs of tripeptides as novel neuraminidase inhibitors. Int J Mol Sci 11:4932\u20134951","journal-title":"Int J Mol Sci"},{"key":"10_CR98","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/DDDT.S30946","volume":"7","author":"PA Gallay","year":"2013","unstructured":"Gallay PA, Lin K (2013) Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther 7:105\u2013115","journal-title":"Drug Des Devel Ther"},{"key":"10_CR99","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1128\/AAC.00939-08","volume":"53","author":"L Coelmont","year":"2009","unstructured":"Coelmont L, Kaptein S, Paeshuyse J, Vliegen I, Dumont JM, Vuagniaux G, Neyts J (2009) Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 53:967\u2013976","journal-title":"Antimicrob Agents Chemother"},{"key":"10_CR100","first-page":"180","volume":"7","author":"RJ Aspinall","year":"2006","unstructured":"Aspinall RJ, Pockros PJ (2006) SCV-07 (SciClone pharmaceuticals\/Verta). Curr Opin Investig Drugs 7:180\u2013185","journal-title":"Curr Opin Investig Drugs"},{"key":"10_CR101","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","volume":"362","author":"JG McHutchison","year":"2010","unstructured":"McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, PROVE3 Study Team (2010) Telaprevir for previously treated chronic HCV infection. N Engl J Med 362:1292\u20131303","journal-title":"N Engl J Med"},{"key":"10_CR102","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364:2417\u20132428","DOI":"10.1056\/NEJMoa1013086"},{"key":"10_CR103","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1021\/jm970873c","volume":"41","author":"G Bold","year":"1998","unstructured":"Bold G, F\u00e4ssler A, Capraro HG, Cozens R, Klimkait T, Lazdins J, Mestan J, Poncioni B, R\u00f6sel J, Stover D, Tintelnot-Blomley M, Acemoglu F, Beck W, Boss E, Eschbach M, H\u00fcrlimann T, Masso E, Roussel S, Ucci-Stoll K, Wyss D, Lang M (1998) New aza-dipeptide analogues as potent. J Med Chem 41:3387\u20133401","journal-title":"J Med Chem"},{"key":"10_CR104","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2165\/00003495-200969080-00009","volume":"69","author":"KF Croom","year":"2009","unstructured":"Croom KF, Dhillon S, Keam SJ (2009) Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 69:1107\u20131140","journal-title":"Drugs"},{"key":"10_CR105","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1111\/j.1440-1746.2004.03635.x","volume":"19","author":"MH Sjogren","year":"2004","unstructured":"Sjogren MH (2004) Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol 19:S69\u2013S72","journal-title":"J Gastroenterol Hepatol"},{"key":"10_CR106","doi-asserted-by":"crossref","unstructured":"Gramenzi A, Cursaro C, Andreone P, Bernardi M (1998) Thymalfasin: clinical pharmacology and antiviral applications. BioDrugs 9:477\u2013486","DOI":"10.2165\/00063030-199809060-00005"},{"key":"10_CR107","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/14787210.2.1.9","volume":"2","author":"RN Chien","year":"2004","unstructured":"Chien RN, Liaw YF (2004) Thymalfasin for the treatment of chronic hepatitis B. Expert Rev Anti-Infect Ther 2:9\u201316","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"10_CR108","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1586\/14787210.3.6.885","volume":"3","author":"VK Rustgi","year":"2005","unstructured":"Rustgi VK (2005) Thymalfasin for the treatment of hepatitis C infection. Expert Rev Anti-Infect Ther 3:885\u2013892","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"10_CR109","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1182\/blood.V93.11.3885","volume":"93","author":"SB Su","year":"1999","unstructured":"Su SB, Gong WH, Gao JL, Shen WP, Grimm MC, Deng X, Murphy PM, Oppenheim JJ, Wang JM (1999) T20\/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Blood 93:3885\u20133892","journal-title":"Blood"},{"key":"10_CR110","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/00002030-200303280-00007","volume":"17","author":"JP Lalezari","year":"2003","unstructured":"Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM (2003) A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17:691\u2013698","journal-title":"AIDS"},{"issue":"8","key":"10_CR111","first-page":"1","volume":"13","author":"H Zhang","year":"2016","unstructured":"Zhang H, Jin R, Yao C, Zhang T, Wang M, Xia W, Peng H, Wang X, Lu R, Wang C, Xie D (2016) Combination of long-acting HIV fusion inhibitor albuvirtide and LPV\/r showed potent efficacy in HIV-1 patients. AIDS Res Ther 13:1\u20134","journal-title":"AIDS Res Ther"}],"container-title":["Advances in Experimental Medicine and Biology","Antiviral Drug Discovery and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-16-0267-2_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T03:05:09Z","timestamp":1675566309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-16-0267-2_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9789811602665","9789811602672"],"references-count":111,"URL":"https:\/\/doi.org\/10.1007\/978-981-16-0267-2_10","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"14 July 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}